GM-CSF & IL-2 ± autologous whole cell vaccine as adjuvant therapy in cutaneous melanoma: A phase II clinical trial

• DOI: 10.1200/jco.2008.26.15_suppl.20027
• Publication Date: 2017-02-24T02:33:44Z
• Authors: S. L. Beam; E. G. Elias; J. L. Zapas; E. C. McCarron; J. H. Hasskamp; W. J. Culpepper
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 3. Good health

20027 Background: The results of various adjuvant trials in high-risk melanoma patients have demonstrated significant improvement in survival, but the results have been inconsistent. GM-CSF and IL-...